intern
travel
zika
viru
zikv
introduc
europ
regularli
countri
abil
robustli
detect
zikv
introduct
local
transmiss
import
minimis
risk
zikv
outbreak
therefor
suffici
expertis
diagnost
capac
capabl
requir
european
laboratori
assess
capac
qualiti
oper
specif
guidelin
algorithm
technic
interpret
issu
possibl
difficulti
relat
zikv
diagnost
european
countri
questionnair
conduct
among
nation
refer
laboratori
countri
european
unioneuropean
econom
area
eueea
may
coverag
capac
zikv
diagnost
eueea
nation
refer
laboratori
found
adequ
assess
qualiti
need
indic
sever
crucial
point
improv
need
support
nation
eueea
level
improv
zikv
prepared
respons
eueea
zikv
surveil
activ
de
arboviru
marseil
zika
viru
zikv
infect
histor
consid
signific
public
health
concern
howev
year
follow
first
autochthon
transmiss
america
zikv
link
sever
congenit
anomali
newborn
neurolog
disord
syndrom
gb
world
health
organ
declar
cluster
microcephali
case
neurolog
disord
possibl
associ
zikv
public
health
emerg
intern
concern
pheic
februari
end
unpreced
zikv
outbreak
affect
countri
territori
america
half
million
human
case
pheic
declar
novemb
argument
zikvassoci
congenit
syndrom
consid
longterm
public
health
challeng
requir
longterm
commit
control
prevent
zikv
mosquitoborn
viru
belong
genu
flaviviru
famili
flavivirida
genom
detect
biolog
sampl
revers
transcript
pcr
rtpcr
viru
isol
cell
cultur
howev
viraemia
typic
shortliv
day
onset
symptom
although
increas
window
detect
observ
use
urin
day
onset
symptom
whole
blood
day
onset
symptom
consequ
full
spectrum
diagnost
includ
serolog
complex
owe
extens
crossreact
antibodi
trigger
flavivir
infect
andor
vaccin
major
zikv
infect
asymptomat
complic
retrac
cours
infect
increas
depend
serolog
confirm
infect
particular
issu
pregnant
women
correct
diagnosi
zikv
infect
even
asymptomat
imper
intern
travel
outbreak
zikv
european
oversea
countri
territori
respons
regular
introduct
zikv
europ
risk
assess
region
offic
europ
whoeurop
indic
risk
outbreak
zikv
europ
underestim
particular
countri
establish
presenc
vector
aed
aegypti
ae
albopictu
countri
abil
robustli
detect
zikv
introduct
local
transmiss
import
minimis
risk
zikv
outbreak
therefor
suffici
expertis
diagnost
capac
capabl
european
laboratori
requir
map
zikv
expertis
identifi
diagnost
capac
capabl
gap
europ
initi
phase
pheic
februari
european
commiss
ec
ask
european
centr
diseas
prevent
control
ecdc
rapid
assess
capac
laboratori
europ
detect
zikv
infect
specif
need
support
assess
done
indepth
questionnair
may
outcom
assess
present
discuss
identifi
knowledg
technic
gap
strengthen
laboratori
capac
qualiti
zikv
diagnost
european
unioneuropean
econom
area
eueea
support
zikv
prepared
respons
well
zikv
surveil
activ
eueea
questionnair
design
address
capac
qualiti
oper
specif
guidelin
algorithm
technic
interpret
issu
possibl
difficulti
relat
zikv
diagnost
nation
refer
laboratori
zikv
diagnost
ask
complet
onlin
questionnair
eueea
ecdc
nation
focal
point
microbiolog
nmfp
questionnair
sent
nmfp
may
close
may
question
questionnair
obligatori
answer
sum
present
data
may
vari
nonrepli
list
total
laboratori
eueea
countri
complet
questionnair
laboratori
countri
indic
conduct
zikv
diagnost
may
figur
zikv
infect
made
notifi
countri
may
mandatori
diseas
notif
plan
near
futur
nine
countri
one
countri
notif
procedur
specifi
agreement
eu
classif
laboratori
indic
oper
biosafeti
level
bsl
zikv
diagnost
eight
laboratori
indic
oper
biosafeti
level
two
laboratori
perform
zikv
diagnost
reason
given
laboratori
deviat
offici
level
downgrad
diagnosi
involv
high
titr
viru
cultur
one
laboratori
ii
upgrad
base
inhous
assess
biosafeti
biosecur
issu
logist
reason
align
zikv
diagnost
flaviviru
diagnost
serolog
viru
isol
three
laboratori
remain
six
laboratori
indic
reason
deviat
time
put
teratogen
effect
zikv
infect
pregnant
women
laboratori
conduct
zikv
diagnost
ask
whether
special
regul
pregnant
employe
place
six
laboratori
answer
question
pregnant
employe
allow
perform
zikv
diagnost
test
three
addit
laboratori
restrict
pregnant
employe
limit
handl
zikv
viru
cultur
remain
laboratori
specif
guidelin
pregnant
employe
laboratori
conduct
zikv
diagnost
n
countri
perform
molecular
test
laboratori
countri
also
conduct
serolog
one
laboratori
perform
antigen
detect
laboratori
accept
differ
type
patient
sampl
includ
plasmaserum
urin
semen
amniot
fluid
placenta
saliva
nasopharyng
swab
number
laboratori
particip
questionnair
invit
countri
nmfp
period
may
indic
per
countri
one
countri
indic
januari
implement
zikv
diagnost
sinc
may
two
countri
without
implement
zikv
diagnost
indic
access
diagnost
agreement
laboratori
anoth
countri
laboratori
receiv
serum
sampl
primari
diagnost
addit
clinician
often
provid
urin
second
sampl
test
semen
saliva
nasopharyng
swab
receiv
lesser
extent
adequ
choic
diagnost
test
run
correct
interpret
result
minimum
inform
patient
histori
requir
laboratori
ask
indic
likert
scale
rang
never
alway
often
certain
essenti
background
inform
patient
sampl
provid
diagnost
request
figur
overal
provis
date
sampl
score
highest
laboratori
score
categori
often
alway
flaviviru
vaccin
statu
score
lowest
score
often
alway
data
essenti
choic
test
algorithm
test
interpret
first
day
ill
countri
date
travel
clinic
symptom
case
women
pregnanc
statu
provid
request
laboratori
laboratori
indic
could
directli
contact
physician
ask
inform
request
sampl
look
record
sheet
laboratori
report
howev
practic
feasibl
strongli
depend
daili
sampl
load
twentyon
laboratori
conduct
zikv
molecular
detect
use
commerci
avail
test
laboratori
inhous
test
nine
laboratori
indic
use
realstar
zika
viru
primari
rtpcr
mostli
carri
singl
zikv
genom
target
howev
two
laboratori
perform
multiplex
pcr
target
multipl
virus
specifi
posit
result
confirm
independ
laboratori
done
either
second
rtpcr
target
differ
genom
segment
laboratori
sequenc
fortythre
laboratori
use
posit
control
obtain
european
viru
archiv
http
wwweuropeanvirusarchivecom
six
robert
koch
institut
via
former
enivd
expert
laboratori
network
patient
materi
use
synthet
rna
four
laboratori
twentytwo
laboratori
indic
use
anoth
posit
control
specif
sourc
eighteen
laboratori
use
zikv
strain
current
outbreak
america
control
use
strain
belong
origin
asian
lineag
african
lineag
strain
use
laboratori
access
one
zikv
lineag
control
zikv
igm
igg
ten
laboratori
countri
abl
assess
presenc
zikv
neutralis
antibodi
plaqu
reduct
neutralis
prnt
andor
viru
neutralis
vnt
test
thirtyon
laboratori
carri
commerci
serolog
assay
laboratori
either
use
euroimmun
ag
antizika
viru
elisa
igmigg
euroimmun
arbovir
fever
mosaic
kit
assay
specifi
assay
use
thirteen
laboratori
use
inhous
assay
includ
elisa
andor
immunofluoresc
assay
ifa
well
vnt
prnt
major
laboratori
indic
obtain
posit
control
materi
patient
sampl
four
laboratori
provid
zikv
igmigg
posit
control
sampl
collabor
gain
insight
level
qualiti
control
laboratori
perform
zikv
diagnost
laboratori
ask
specifi
level
laboratori
accredit
analysi
laboratori
level
show
intern
organ
standard
iso
medic
laboratori
requir
qualiti
compet
anoth
qualiti
aspect
concern
extent
valid
implement
diagnost
particular
serolog
view
extens
crossreact
median
size
inhous
valid
panel
confirm
zikv
wnv
patient
small
tabl
serum
sampl
pregnant
women
popul
panel
zikvendem
region
lack
laboratori
tabl
thirtyseven
laboratori
indic
will
share
valid
data
laboratori
howev
zikv
diagnost
laboratori
indic
accredit
scheme
accept
valid
done
elsewher
would
possibl
option
laboratori
laboratori
ask
indic
mani
diagnost
sampl
could
process
per
week
differ
type
test
run
figur
diagnost
capac
individu
laboratori
differ
depend
type
diagnost
test
addit
laboratori
ask
mani
sampl
process
determin
posit
molecular
igm
igg
neutralis
antibodi
test
sinc
januari
tabl
laboratori
offer
molecular
test
cumul
number
total
request
period
cover
questionnair
includ
request
support
laboratori
remain
indic
capac
per
week
laboratori
cumul
number
request
approxim
two
three
time
indic
weekli
capac
three
laboratori
exceed
capac
five
serolog
vast
major
laboratori
cumul
number
request
period
two
three
time
weekli
capac
fourteen
laboratori
indic
support
laboratori
perform
molecular
test
fifteen
laboratori
support
other
serolog
test
laboratori
provis
control
materi
major
laboratori
offer
laboratori
support
laboratori
mainli
implement
zikv
test
algorithm
either
advis
ecdc
nation
public
health
institut
remain
eight
laboratori
follow
among
algorithm
zikv
diagnost
algorithm
advis
pan
american
health
organ
paho
case
necessari
background
inform
first
day
ill
known
ten
diagnost
laboratori
perform
molecular
serolog
test
avail
sampl
three
alway
carri
serolog
two
alway
perform
rtpcr
three
conduct
test
ask
clinician
ten
laboratori
either
ask
inform
addit
sampl
patient
interpret
base
kinet
remain
provid
answer
laboratori
also
ask
differ
test
algorithm
asymptomat
pregnant
women
put
zikv
exposur
ten
laboratori
indic
ask
pair
serum
sampl
asymptomat
pregnant
women
serolog
laboratori
molecular
serolog
test
avail
sampl
eight
laboratori
refer
nation
zikv
diagnost
algorithm
one
laboratori
indic
asymptomat
patient
never
test
regardless
pregnanc
statu
laboratori
ask
describ
main
challeng
face
implement
zikv
molecular
andor
serolog
diagnost
main
indic
obstacl
avail
posit
control
valid
materi
molecular
serolog
test
avail
commerci
serolog
test
personnel
capac
figur
may
eueeawid
coverag
zikv
molecular
diagnost
three
countri
without
incountri
zikv
molecular
diagnost
access
diagnost
agreement
laboratori
anoth
countri
two
plan
implement
zikv
diagnost
near
futur
one
countri
implement
zikv
molecular
diagnost
januari
figur
comparison
februari
snapshot
ec
data
shown
four
eueea
countri
implement
zikv
molecular
diagnost
may
coverag
zikv
serolog
increas
eueea
countri
access
zikv
serolog
particularli
import
confirm
rule
zikv
infect
pregnanc
essenti
medic
followup
regard
teratogen
zikv
estim
zikv
infect
asymptomat
genom
detect
window
serum
short
zikv
diagnosi
pregnant
women
often
reli
zikv
antibodi
detect
pair
serum
sampl
import
aspect
conduct
zikv
serolog
expertis
flavivirus
interpret
complex
laboratori
conduct
zikv
serolog
indic
experi
serodiagnost
least
one
flaviviru
addit
insight
specif
sensit
serolog
test
use
requir
proper
test
interpret
appear
limit
time
questionnair
adequ
valid
panel
lack
valid
data
provid
commerci
entiti
typic
need
confirm
order
accept
accredit
scheme
similarli
valid
assay
perform
anoth
laboratori
may
insuffici
meet
accredit
requir
inde
avail
valid
panel
serolog
indic
biggest
challeng
implement
zikv
diagnost
zikv
diagnost
laboratori
five
zikv
diagnost
laboratori
kind
iso
accredit
laboratori
relev
iso
accredit
anoth
concern
broad
relianc
zikv
serolog
one
two
commerci
test
although
note
may
commerci
market
zikv
serolog
offer
limit
option
decemb
commerci
serolog
test
accept
procur
emerg
use
assess
list
procedur
requir
extens
valid
illustr
import
refer
laboratori
capac
viru
neutralis
still
consid
specif
flaviviru
serolog
test
although
crossreact
observ
patient
flaviviru
infect
research
ongo
develop
specif
assay
broad
implement
confirmatori
test
eueea
nation
refer
laboratori
howev
expect
increas
reliabl
serolog
result
return
travel
flaviviru
background
particular
dengu
european
travel
like
low
molecular
test
capacitycap
diagnos
zikv
reli
laboratori
commerci
assay
laboratori
inhous
test
nine
laboratori
commerci
inhous
test
one
lanciotti
et
al
two
inhous
test
frequent
use
recommend
base
silico
analysi
independ
compar
studi
zikv
molecular
test
rais
possibl
concern
perform
diagnost
laboratori
novemb
ecdcfund
emerg
viral
diseas
laboratori
expert
network
evdlabnet
organis
extern
qualiti
assess
eqa
member
laboratori
includ
major
nation
refer
laboratori
zikv
diagnost
particip
questionnair
result
eqa
provid
point
improv
individu
laboratori
adequ
choic
type
test
use
correct
interpret
test
result
defin
set
inform
patient
histori
essenti
shown
diagnost
lack
inform
provid
clinician
request
diagnost
prove
major
gap
although
date
sampl
given
often
score
often
alway
inform
hardli
meaning
without
indic
first
day
ill
score
highest
categori
laboratori
reliabl
interpret
zikv
serolog
imped
without
inform
previou
flaviviru
infect
vaccin
oftenalway
avail
laboratori
reimburs
rule
diagnost
test
differ
countri
data
shown
state
cover
cost
diagnost
test
provis
necessari
background
inform
mandatori
overal
zikv
diagnost
capac
eueea
countri
appear
suffici
given
total
number
report
request
vs
indic
capac
countri
level
extent
underovercapac
vari
complic
fact
laboratori
certain
iso
accredit
bound
strict
regul
send
surplu
sampl
backup
laboratori
avail
valid
materi
posit
control
personnel
indic
main
challeng
implement
zikv
diagnost
refer
laboratori
eueea
countri
laboratori
indic
cost
commerci
test
obstacl
test
implement
larg
depend
laboratori
commerci
assay
five
laboratori
receiv
fund
develop
andor
implement
inhous
test
illustr
achil
heel
prepared
emerg
infect
need
care
consider
defin
strategi
strengthen
laboratori
prepared
respons
futur
outbreak
situat
coverag
capac
zikv
diagnost
eueea
nation
refer
laboratori
observ
suffic
may
assess
qualiti
need
indic
sever
crucial
point
improv
need
support
nation
eueea
level
refer
laboratori
seek
relev
iso
accredit
awar
facilit
temporari
accept
laboratori
accredit
novel
diagnost
implement
emerg
situat
requir
although
current
hamper
lack
avail
welldefin
valid
panel
improv
access
requir
control
valid
panel
molecular
serolog
test
pend
develop
specif
serolog
test
broader
implement
current
specif
neutralis
test
prnt
vnt
desir
ideal
compar
set
relev
flavivirus
increas
awar
need
among
clinician
provid
necessari
background
inform
system
implement
assur
provis
necessari
interpret
data
nation
eu
conting
fund
establish
ensur
adequ
robust
laboratori
prepared
respons
